Indications And Dose
Malignant disease ▶BY INTRAVENOUS INFUSION ▶Adult: (consult local protocol)
PDF page 969
Loading InternPractice…
Drug reference
Malignant disease ▶BY INTRAVENOUS INFUSION ▶Adult: (consult local protocol)
PDF page 969
Acute infection. cystitis. urinary- tract obstruction. urothelial damage
PDF page 969
Avoid in Acute porphyrias p. 1120. diabetes mellitus
PDF page 969
→Appendix 1: alkylating agents
PDF page 969
▶Common or very common Alopecia. appetite decreased. bone marrow disorders. haemorrhage. hepatic disorders. infection. leucopenia. nausea. reactivation of infection. renal impairment. thrombocytopenia. vomiting ▶Uncommon Cardiotoxicity. diarrhoea. hypotension. oral disorders ▶Rare or very rare Skin reactions ▶Frequency not known Abdominal pain. agranulocytosis. amenorrhoea. anaemia. angina pectoris. angioedema. arrhythmias. arthralgia. asterixis. behaviour abnormal. blood disorders. bone disorders. cancer progression. capillary leak syndrome. cardiac arrest. cardiomyopathy. chills. conjunctivitis. constipation. cough. deafness. delirium. delusions. disseminated intravascular coagulation. dysarthria. dyspnoea. electrolyte imbalance. embolism and thrombosis. encephalopathy. eye irritation . fatigue. fever. flushing. gait abnormal. gastrointestinal disorders. growth retardation. haemolytic anaemia. heart failure. hyperglycaemia. hyperhidrosis. hyperphosphaturia. hypertension. hypoxia. immunosuppression. infertility. malaise. mania. memory loss. metabolic acidosis. movement disorders. mucosal ulceration. multi organ failure. muscle complaints. myocardial infarction. nail disorder. neoplasms. nephritis tubulointerstitial. nephrogenic diabetes insipidus. neurotoxicity. oedema. ovarian and fallopian tube disorders. pain. pancreatitis. panic attack. peripheral neuropathy. polydipsia. premature menopause. psychiatric disorders. pulmonary hypertension. pulmonary oedema. radiation recall reaction. respiratory disorders. rhabdomyolysis. secondary malignancy. sensation abnormal. sepsis. severe cutaneous adverse reactions (SCARs). SIADH. sinusoidal obstruction syndrome. sperm abnormalities. status epilepticus. tinnitus. tumour lysis syndrome. urinary disorders. vasculitis. vertigo. visual impairment SIDE-EFFECTS, FURTHER INFORMATION Urothelial toxicity Mesna is routinely given with ifosfamide to reduce urothelial toxicity. Secondary malignancy Use of ifosfamide is associated with an increased incidence of acute leukaemia.
PDF page 969
Manufacturer advises adequate contraception during and for at least 6 months Immune system and malignant disease after treatment in men or women. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 969
Avoid (teratogenic and carcinogenic in animals). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 969
Discontinue breast-feeding.
PDF page 969
Manufacturer advises avoid.
PDF page 969
Avoid if serum creatinine concentration greater than 120 micromol/litre.
PDF page 969
Ensure satisfactory electrolyte balance and renal function before each course (risk of tubular dysfunction, Fanconi’s syndrome or diabetes insipidus if renal toxicity not treated promptly).
PDF page 969
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for injection ▶Ifosfamide (Non-proprietary) Ifosfamide 1 gram Ifosfamide 1g powder for concentrate for solution for injection vials | 1 vial P £115.79–£119.27 Ifosfamide 2 gram Ifosfamide 2g powder for concentrate for solution for injection vials | 1 vial P £228.09–£234.94
PDF page 969
(consult local protocol)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 969